BRIEF—Oxford Biomedica and Juno Therapeutics expand collaboration

Cell and gene therapy companies Oxford Biomedica and Juno Therapeutics have expanded their research agreement to include two new viral vector programs for CAR-T cell treatments, taking the total to six.

Juno, a subsidiary of Bristol Myers Squibb, started working with the British firm in March 2020, gaining a non-exclusive license to Oxford’s LentiVector platform for use in oncology and other indications.

Oxford Biomedica will now receive an undisclosed target nomination fee, as well as potential payments based on other milestones.

The firm’s chief executive, Roch Doliveux, said Bristol Myers was “a strategically important partner,” and “a proven commercial and clinical leader in the CAR-T field.”